Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes

Britta Höchsmann, Markus Rojewski, Hubert Schrezenmeier

To cite this version:
Britta Höchsmann, Markus Rojewski, Hubert Schrezenmeier. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Annals of Hematology, Springer Verlag, 2011, 90 (8), pp.887-899. 10.1007/s00277-011-1177-4. hal-00617077

HAL Id: hal-00617077
https://hal.archives-ouvertes.fr/hal-00617077
Submitted on 26 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes

1Britta Höchsmann, 2Markus Rojewski and 1Hubert Schrezenmeier
1DRK-Blood Donor Service, Baden-Württemberg-Hessia, Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, and 2Institute of Transfusion Medicine; University of Ulm, Ulm; Germany

Correspondence: Britta Höchsmann, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Helmholtzstraße 10, 89081 Ulm, Germany, e-mail: b.hoechsmann@blutspende.de

Acknowledgments: The authors would like to thank Gisela Baur, Thomas Becker and Rosi Leichtle for skilful technical and statistical evaluation assistance.

BH and HS contributed equally to this manuscript.
Abstract:

Background:
Flow cytometric analysis of GPI-anchored proteins (GPI-AP) is the gold standard for diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH). Due to therapy options and the relevance of GPI-deficient clones for prognosis in Aplastic Anemia detection of PNH is gaining in importance. However, no generally accepted standard has been established.

Design and Methods:
This study analysed the usefulness of a flow cytometric panel with CD58, CD59 on reticulocytes and erythrocytes, CD24/CD66b and CD16, FLAER on granulocytes and CD14, CD48 on monocytes. Actual cut off (mean + 2 SD) for GPI-deficient cells was established in healthy blood donors. We studied 1296 flow cytometric results of 803 patients. Serial monitoring was analysed during a median follow up of 1039 days in 155 pts.

Results:
Twenty-two % of all and 48 % of 155 follow-up pts showed significant GPI-AP-deficiency at time of initial analyses. During follow up in 9% a new PNH-diagnosis and in 28% a significant change of size or lineage involvement was demonstrated. Highly significant correlations for GPI-AP deficiency were found within one cell lineage ($r^2 = 0.61 - 0.95, p < 0.0001$) and between the different cell lineages ($r^2 = 0.49 – 0.88, p < 0.0001$).

Conclusions:
Especially for detection of small GPI-deficient populations reticulocytes and monocytes proved to be sensitive diagnostic tools. Our data showed superiority of reticulocyte analyses compared with erythrocyte analyses due to transfusion and hemolysis independency especially in cases with small GPI-deficient populations. In conclusion a screening panel of at least two different GPI-AP markers on granulocytes, erythrocytes and reticulocytes provides a simple and rapid method to detect even small GPI-deficient populations. Among the markers in our panel CD58 and CD59 on reticulocytes, CD24/66b and eventually FLAER on granulocytes as well as CD14 on monocytes were most effective for flow cytometric diagnosis of GPI-deficiency.

Keywords: PNH, Paroxysmal nocturnal hemoglobinuria, flow cytometry, immunophenotyping, Glycosylphophatidyl-inositol anchor, GPI deficiency, reticulocytes
Introduction:
Paroxysmal Nocturnal Hemoglobinuria (PNH) is an acquired hematopoietic stem cell disease (1, 2). Pathophysiologically it is based on somatic mutations of the X-linked phosphatidyl-inositol-glycan (PIG-A) gene (3, 4) which result in a partial or absolute deficiency of GPI-linked proteins (5). The lack of GPI-linked proteins leads to the clinical features chronic intravascular hemolytic anemia and thromboembolism (32, 33). The role of GPI-AP in bone marrow failure which is often associated with PNH is less clear(6).
Measurement of GPI-anchored proteins expression by flow cytometry is nowadays the gold standard for laboratory diagnosis of PNH and has replaced the Ham test and the sucrose lysis test (sugar water test) (7, 8). Flow cytometry allows a sensitive and specific detection of even small GPI-deficient populations and a quantification of PNH cell populations in various cell lineages. This quantification is especially important, as the estimated size and type of the involved cell lineages correlates with different clinical manifestations of the disease (14). For instance patients with more than 20% type III deficiency on red cells mostly have clinically significant hemolysis, while nearly half of pts with more than 50% GPI-deficiency on the granulocytes suffer from venous thrombosis in the first ten years after initial diagnosis (15). Therefore the size of the GPI-AP deficient population on granulocytes is a prognostic factor for vascular events, which have been shown to be the key determinant of prognosis with the most important impact on life expectancy. Remarkably, clone size and cell lineage involvement can change over time (6, 12, 21). This leads to the need of follow up investigations to initiate appropriate therapeutic approaches. Beside initial diagnosis flow cytometry in particular enables serial monitoring during the course of the disease (9, 10, 11, 12). This allows ontime determination of therapeutic decisions like initiation of prophylactic anticoagulation (15) or application of the C5-antibody eculizumab, which has already proven to reduce hemolytic activity and thrombembolic events (16 - 19). Additionally therapeutic effects may be monitored via flow cytometric analysis of GPI-deficiency. Disappearance of the GPI-deficient populations indicates effective therapy after stem cell transplantation while increase of the GPI-deficient erythrocyte-populations upon eculizumab therapy is presumable due to a decrease of hemolytic activity with the result of a prolonged red blood cell (RBC)-survival
Although flow cytometric analysis of GPI-AP is the gold standard for diagnosis of PNH for years, there are no detailed international or even nationwide rules to determine minimal demands for PNH diagnosis based on flow cytometry. There exists just a general advice of the International PNH Interest Group (IPIG) to examine at least erythrocytes and granulocytes for diagnosis of PNH (21). No consensus recommendations are available for the choice of GPI-AP markers or even the cell populations which should be examined. Thus, results from different laboratories are often difficult to compare and false negative or false positive results are not a rare event. Moreover most tests are influenced by hemolytic crises or RBC transfusions as they rely on GPI-deficiency of erythrocytes. Therefore, in this study we retrospectively analysed the results of our routine diagnostics of the last 5 years to assess the most suitable GPI-markers and cell populations for a sensitive, valid and rapid GPI-AP flow cytometric analysis for diagnosis and serial testing.

**Design and Methods:**

**Patients:**

Flow cytometric GPI-AP analysis was performed in 803 patients suffering from PNH or suspected GPI-deficient populations. The reason for flow cytometric analysis as reported by the treating physician were the following diagnoses or suspected diagnoses: PNH in 67 patients, hemolysis in 77 patients, Aplastic Anemia or trilineage cytopenia in 291 patients, MDS in 44 patients, single lineage or bilineage cytopenia in 76 patients, unclear thromboembolic events or ischemias in 49 patients, other hematologic diseases in 25 patients and insufficient information in 174 patients. In the majority of the patients, blood was sent for routine diagnostic assessment to our reference diagnostic laboratory at the Institute of Clinical Transfusion Medicine and Immunogenetics Ulm for analysis of GPI deficiency as a diagnostic routine procedure in patients with bone marrow failure, hemolytic anemia, iron deficiency anemia, thrombosis or abdominal pain of unknown origin. Some of the analyses were performed as diagnostic test in clinical trials after informed consent and ethical committee approval of the trial. Patients were included in the follow-up analysis if at least two GPI-AP assessments with a minimum interval of three months were available (n=155 pts). At time of initial GPI-AP-analysis blood count was
available in 89 of the 155 follow up pts.; in this pts group 48/89 pts showed neutropenia with < 0.5 G/l and 70/89 pts had thrombopenia with < 100 G/l. Patients with eculizumab treatment were censored at the date of first eculizumab application and GPI-AP assessment of these patients during eculizumab therapy were not included in the analyses presented here. Five patients who received allogeneic stem cell transplantation were not censored for analysis. The pattern of lineage involvement and the suitability of various lineages and markers in the peripheral blood for detection of GPI-deficient populations were statistical analysed retrospectively in all patients. For follow-up the size of GPI-deficient populations as well as the evolution of lineage involvement was investigated.

**Two Color Flow Cytometry:**

Immunophenotyping was performed as previously described. (12) 1296 flow cytometric examinations performed between March 2003 and August 2008 were analysed. Peripheral blood (PB) was obtained by venous puncture using Na-EDTA or citrate as anti-coagulant. All incubations were performed at room temperature in the dark. We used the flow cytometric analysis of CD58 and CD59 on reticulocytes and erythrocytes and of CD66b/CD24 and CD16 on granulocytes as mandatory markers for our screening panel. The expressions of CD14 and CD48 on monocytes as well as CD48/CD19 and CD48/CD3 on lymphocytes were used as optional markers to fully assess lineage involvement. In 584 cases a combination of CD66b/CD24, CD16 and FLAER, a fluorochrome-labelled modified bacterial toxin which binds directly to the GPI-anchor was used to confirm the diagnosis. Staining of the reticulocytes by the RNA dye thiazol orange allowed a separate analysis of erythroctes and reticulocytes.

**Staining of erythrocytes and reticulocytes (no wash, stain, no lyse protocol):**

A volume of 100 µL of 1:10 diluted PB in PBS without Ca\(^{2+}\)/Mg\(^{2+}\) (PAA Laboratories, Paching, Austria) was used for each assay. As isotype control, diluted PB was incubated with 20 µL of IgG*PE, clone X40 (BD Immunocytometry Systems, Heidelberg, Germany). Detection of GPI-deficient erythrocytes and reticulocytes was performed by staining 100 µL of diluted PB
with either 20 µL of CD58*PE, clone AICD58 (Beckman Coulter Immunotech, Krefeld, Germany) or 20 µL of CD*59 PE, clone p282 (H19) (BD Pharmingen, Heidelberg, Germany). After 20 min, cells were washed once by addition of 1 mL PBS without Ca\(^{2+}\)/Mg\(^{2+}\) followed by centrifugation at 5900 g for 0.5 - 1 min. The cells of all three assays were resuspended in 1 mL of ReticCOUNT Reagent (BD Immunocytometry Systems) and incubated for 20 min - 1 h to stain RNA of reticulocytes before analysis by flow cytometry (figure 1).

**Staining of granulocytes, monocytes (no wash, stain, lyse protocol):**
To consider the contribution of different autofluorescences, separate isotype controls were performed for granulocytes, monocytes Therefore, two assays of PB, containing 0.8x10\(^6\) - 1.6x10\(^6\) leucocytes each, were incubated with 20 µL of IgG*FITC and 20 µL of IgG* PE clone X40 (both BD Immunocytometry Systems). Analysis of granulocytes was performed by staining PB with 10 µL of CD24*FITC, clone SN3 (DAKO, Hamburg, Germany), 10 µL of CD66b*FITC, clone 80H3 (Beckman Coulter Immunotech) and 20 µL of CD11b*PE, clone D12 (BD Immunocytometry Systems). In a separate assay, the corresponding amount of PB was incubated with 10 µL of CD16*FITC, clone NKP15 and 20 µL of CD11b*PE, clone D12 (both BD Immunocytometry Systems). For analysis of monocytes, PB was incubated either with 20 µL of CD14*FITC, clone MOP9 and 20 µL of CD33*PE, clone P67.6 (both BD Immunocytometry Systems) or 20 µL of CD48*FITC, clone J4.57 (Beckman Coulter Immunotech) and 20 µL*CD33, clone P67.6 (BD Immunocytometry Systems), respectively. After 20 - 30 min, cells were washed once by addition of 1 mL PBS without Ca\(^{2+}\)/Mg\(^{2+}\) and centrifugation by 5900 g for 0.5 - 1 min. Lysis of erythrocytes was performed by resuspension of the cell pellets in 100 µL OptiLyse B (Beckman Coulter Immunotech), incubation for 7 - 15 min, addition of 1 mL aqua followed by vigorous mixing and incubation for another 5 - 15 min. After lysis of erythrocytes, cells were washed twice using 1 mL PBS without Ca\(^{2+}\)/Mg\(^{2+}\) and resuspended 300 - 800 µL PBS without Ca\(^{2+}\)/Mg\(^{2+}\) for flow cytometry analysis.

**Staining of granulocytes (wash, lyse, stain protocol):**
For detection of GPI-deficient granulocytes by FLAER (FITC labeled aerolysin, Protox Biotech, Victoria, Canada), a volume of PB blood containig approximately
2x10^5 neutrophiles was washed with the 5-fold volume of PBS without Ca^{2+}/Mg^{2+} and the supernatant was discarded. Erythrocytes were lysed as described above using half the volume of OptiLyse B and aqua and washed twice, using PBS without Ca^{2+}/Mg^{2+}. Half of the remaining cells were stained with 2 - 5 µL of a 1:10 dilution of IgG*PE, clone X40 (BD Immunocytometry Systems) in PBS, the other half of the cells was stained with a 1:50 dilution of CD16*PE, clone 3G8 (BD Pharmingen) in PBS and 0.5 - 5 µL FLAER, respectively. After 20 - 30 min, 1 mL of PBS without Ca^{2+}/Mg^{2+} was added, supernatant was removed after centrifugation at 5900 g for 30 sec - 1 min and cells were resuspended in 300 - 800 µL of PBS without Ca^{2+}/Mg^{2+}.

**Normal range – cut off values of GPI-deficiency**

In the 5 – year observation period every week healthy blood donors (overall n= 268) were tested for GPI-deficiency to establish cut-off values (mean + 2 SD) for GPI-deficient cells. In respect of variabilities in antibody efficiency we updated this cut off every 6 months with the results of the last 50-60 examined healthy donors. The valid cut offs at the end of the 5- year observation period (overall results of the 268 healthy donors were put in parantheses) were: reticulocytes CD58: 0.5% (1.0%), reticulocytes CD 59: 1.9% (2.0%), erythrocytes CD58: 0.1% (0.2%), erythrocytes CD59: 0.5% (0.8%), granulocytes CD66b/CD24: 0.1% (0.7%), granulocytes CD16: 1.0 % (1.2%), granulocytes FLAER*,CD16: 0.3 % (1.2%); monocytes CD14: 2.5 % (3.3%), monocytes CD48: 1.1% (1.1%);

For flow cytometric diagnosis of a PNH cell population at least two cell lineages with significant GPI-deficient populations were required. Significant GPI-deficient populations are defined if all examined markers (minimum: 2) were exceeding the cut off value.

**Statistical analysis:**

Statistical analyses of the data were carried out in Microsoft Office Access 2003 and GraphPad PRISM, version 4.00. Used tests were linear regression, including correlations, coefficient of correlation and confidence interval as well as scatter plots. A p-value off less than 0.05 was considered as statistically significant.
**Results:**

**Patient characteristics**

Patient characteristics for the examined 803 pts (416 male; 382 female) were as follows: the patient age ranged from 0.4 to 90.7 years (median age: 32.4 years) with no relevant differences between men (52%) and women (48%) (table 1). At initial GPI-AP-flow cytometry 176 of all patients (22%) were diagnosed with PNH typical GPI-deficient populations (figure 2). The groups with and without PNH diagnosis at time of initial GPI-AP-analysis do not differ significantly in age and sex distribution. For detailed patient characteristics see table 1.

In the follow up cohort 155 pts and 625 flow cytometric analyses were evaluated (median number of analyses per patient: 3; range from 2 to 26) for a median follow up duration of 1039 days. Patient characteristics of the follow up group are summarized in table 1.

Blood count was evaluable in 89 of these pts at the time of initial assessment and in 120 pts at time of the last examination. Thrombocytopenia < 100 G/l was obtained in 62% at the initial examination and in 43% at the last examination. Leukocytopenia < 0.5 G/l was initially obtained in 36% and decreased to 18% at the final investigation (see data supplements).

**Flow cytometric results**

*Analysis of different GPI-anchored markers in the same cell lineage*

Primarily, we compared all flow cytometric results (including the follow-up analyses) within each separate cell lineage to assess the correlation of the various GPI-linked markers. We found a highly significant correlation between the markers CD58 and CD59 on reticulocytes ($r^2 = 0.95$, $p < 0.0001$; $n=1284$) and erythrocytes ($r^2 = 0.86$, $p < 0.0001$; $n = 1284$), between CD24/66b and CD16 or between CD24/66b and CD16, FLAER on granulocytes ($r^2 = 0.76$, $p < 0.0001$; $n = 1248$) and between CD14 and CD48 on monocytes ($r^2 = 0.62$, $p < 0.0001$; $n = 599$) (figure 3). If we restricted the analysis to the first GPI-AP-flow cytometric analysis in each patient, the correlation did not change considerably (figure 3).

*Marker analysis between different cell lineages*

In a second step we compared the sizes of various GPI-marker negative populations in different cell lineages. This analysis was initially performed for all
GPI-AP-flow cytometric results in patients with flow cytometric diagnosis of PNH. The following significant correlations were obtained: CD58-negative reticulocytes and CD58-negative erythrocytes (n = 457, \( r^2 = 0.63, p < 0.0001 \)), CD59-negative reticulocytes and CD59-negative erythrocytes (n = 455, \( r^2 = 0.61, p < 0.0001 \)), CD59-negative reticulocytes and CD24/D66b-negative granulocytes (n = 450, \( r^2 = 0.60, p < 0.0001 \)), CD59-negative reticulocytes and CD14-negative monocytes (n= 381, \( r^2 = 0.68, p < 0.0001 \)), CD59-negative erythrocytes and CD24/66b-negative granulocytes (n = 449, \( r^2 = 0.33, p < 0.0001 \)), CD14-negative monocytes and CD24/66b–negative granulocytes (n = 423, \( r^2 = 0.84, p < 0.0001 \)), CD 48-negative monocytes and CD24/66b-negative granulocytes (n = 421, \( r^2 = 0.48, p < 0.0001 \)), (Figure 4).

In a second step the analysis was restricted to the first flow cytometric analysis of each patient with flow cytometric diagnosis of PNH. There were no significant differences between both analyses (figure 4).

**Marker analysis for detection of small GPI-deficient populations**

To elucidate the importance of individual markers for the flow cytometric diagnosis of PNH all markers were separately analyzed. Depending on the size of the CD24/CD66b-negative granulocyte population we defined two different subgroups based on a CD24/CD66b-negative granulocyte population < 10% or ≥ 10% at the first investigation. The largest median GPI-deficient population in the subgroup with < 10% CD24/66b-negative granulocyte populations was observed for CD14 on monocytes, CD16 or CD16, FLAER on granulocytes and CD59 on reticulocytes. In the subgroup with ≥ 10% CD24/CD66b-negative-granulocyte population the largest median GPI-deficient population was shown for CD14 on monocytes, CD24/66b and CD16 as well as CD16, FLAER on granulocytes and CD59 on reticulocytes (figure 5).

**Follow up analysis**

We analysed repeated measurements of GPI-AP expression on reticulocytes, erythrocytes, granulocytes and monocytes in 155 pts (figure 6) in order to study the dynamics of GPI-AP deficient cell populations over time. Since it has been demonstrated that treatment with eculizumab changes the relative proportion of GPI-AP deficient red cells (19), patients who received eculizumab treatment...
were censored at start of this treatment. Median number of analyses per pt was 3 and the median follow up duration was 1039 days (minimum 90 days, maximum 1903 days). Initially 75 (48%) of these pts were diagnosed with PNH. The longitudinal studies revealed different patterns of GPI-AP-expression during the follow up period (figure 2, figure 6, figure 7): (A) no significant GPI-AP deficiency fulfilling our criteria for flow cytometric PNH diagnosis during the whole investigation period; (B) new flow cytometric diagnosis of PNH during follow up after a normal GPI-AP-expression at first investigation; (C) flow cytometric diagnosis of PNH at initial analysis with stable size of GPI-deficient granulocyte population during follow up (defined as GPI-deficient granulocyte population stable \(< 50\%\) or \(\geq 50\%\)); (D) flow cytometric diagnosis of PNH at initial analysis with expansion of the GPI-deficient granulocyte population (defined as increase of GPI-deficient granulocyte population from \(< 50\%\) to \(\geq 50\%\)) (D1) and/or involvement of additional cell lineages (D2) during follow up; (E) flow cytometric diagnosis of PNH at initial analysis and decrease of the GPI-deficient granulocyte population (defined as decrease of GPI-deficient granulocyte population from \(\geq 50\%\) to \(< 50\%\)); (E1) or disappearance of GPI-deficiency in a cell lineage (E2) during longitudinal analysis; (F) disappearance of the PNH-typical GPI-AP deficiency below our criteria for flow cytometric PNH diagnosis. The cut off granulocyte clone size of \(</\> 50\%\) as sign of a relevant quantitative change in clone size was chosen because of published data about the impact of this relative proportion for thromboembolic events (15). Patient characteristics, number of examinations and duration of follow up are summarized in table 1. In detail 9\% of the 80 pts with no PNH-typical GPI-AP deficiency in the first analysis developed flow cytometric PNH diagnosis during follow-up (group B). In 3 of these 7 cases detected during follow up diagnosis was based on significant GPI-AP deficient populations on monocytes and granulocytes. 28\% of the follow up patients showed a significant change of GPI-AP deficiency on granulocytes or lineage involvement. Moreover 5 out of the 75 pts initially diagnosed with PNH developed an emerging GPI-deficient population on an additional cell lineage or showed less involved cell lineages during follow up (group D2 and E2). In 11 \% of all cases with flow cytometric diagnosis of PNH a significant change of GPI-deficient granulocyte population occurred (group D1 and E1). In the group of the 7 pts with decrease of GPI-deficient granulocyte
population or disappearance of significant GPI-AP deficiency in a cell line (E1 and E2) 2 pts received allogeneic stem cell transplantation and 2 pts were treated with ATG-based immunosuppressive therapy. Only 3 of these 7 pts suffered from a classical PNH, while 4 were diagnosed with associated bone marrow failure syndromes. All 3 pts with classical PNH showed a decrease of GPI-AP deficient population on granulocytes and no change in cell lineage involvement. Additionally 8 pts (11 %) fulfilled no longer the flow cytometric criteria of PNH during follow up (group F). Half of these 8 pts received an ATG-based immunosuppression and 4 pts (one was treated for MDS) received an allogeneic stem cell transplantation before the PNH-typical GPI-AP deficient population pattern disappeared. A spontaneous loss of significant GPI-deficiency clones, i.e. disappearance without prior therapy, was observed in none of the follow up pts. All such cases were obtained in association with therapy response and blood count improvement.

**Discussion:**

Flow cytometry of GPI-AP is considered to be the gold standard of PNH diagnosis. CD55- and CD59-expression on erythrocytes are most frequently used for screening of PNH (6 - 7, 9 - 14, 21, 22). Our presented data show that addition of further antibodies against GPI-linked antigens on different cell lineages considerably improves the sensitivity and validity of the method. Among the markers evaluated we recommend a panel including at least the following markers: CD58 and CD59 for reticulocytes and erythrocytes a combination of CD24/66b and eventually FLAER on the granulocytes and CD14 on monocytes. It has been shown that detection of GPI-deficient reticulocytes is more sensitive than analysis of erythrocytes. And reticulocytes better correlates with proportion of GPI-deficient white cells. The remarkable worse correlation between erythrocytes and granulocytes compared to the correlation of reticulocytes and granulocytes (figure 4) and the larger GPI-deficient populations in reticulocyte than erythrocyte (figure 5) are probably caused by RBC transfusions, hemolytic crises and a shorter life span of PNH erythrocytes (24, 25). As reticulocytes are less affected by these events their examination for GPI-AP-deficiency is especially suitable for diagnosis of involvement of the red cell lineage if there are small GPI-deficient granulocyte populations below 10%. Nevertheless the most
international recommendations for flow cytometry still favour erythrocyte analysis. Our data emphasize the importance of reticulocyte analysis. Even if reticulocyte clone size correlates well with white cell clone size both should be tested to confirm the flow cytometric diagnosis of PNH because alteration of GPI-AP on leukocytes can be a sign of granulocytic/monocytic dysplasia and immaturity (31, data supplements) in the context of various myeloid diseases or cytosis. Due to our results participation of leukocytes is detected best by examination of CD14-deficiency on monocytes (figure 5). Therefore additional examination of monocytes provides a higher detection sensitivity of GPI-AP deficiency especially in pts with small GPI-deficient granulocyte populations < 10%. In fact the marker combination CD24/66b and CD16 seems to be suitable in sensitivity and validity to detect GPI-deficient granulocytes in our analysis.

Follow-up examination is recommended by the International PNH Interest Group (IPIG) in case of bone marrow failure syndromes (21) even in case of initially normal flow cytometric analysis. Moreover, regular follow up studies are indicated in case of known PNH to detect substantial changes in GPI-AP deficient population size or cell lineage involvement, as both situations may prompt therapeutic consequences or may demonstrate effect of therapeutic interventions. Therefore, we evaluated our panel on different cell lineages for longitudinal monitoring of GPI-deficient populations to determine the frequency of significant changes in cell lineage involvement and GPI-deficient population size. Our definition of a relevant change in GPI-deficient population size (</= 50% GPI-deficiency on granulocytes) is based on data published by Hall et al. (15) demonstrating that pts with a GPI-deficient population on granulocytes > 50% have a significant higher risk of thromboembolic events. Our results again support the importance of GPI-AP measurement on reticulocytes to obtain results independent of hemolytic crisis and RBC transfusions.

The described flow cytometry panel could be used for serial monitoring during follow up to detect evolution of GPI-AP deficient populations and to assess therapy effects. Although follow-up investigations were performed only in a minority of patients with initially normal results (80 out of 627pts), in 7 of the follow up patients PNH was newly diagnosed. Based on our follow up data with a relevant proportion of newly developing GPI-AP deficient populations and significant changes in the size of GPI-AP deficient populations repeated GPI-AP-
analysis in regular intervals should be performed, like it is recommended by the International PNH Interest Group (IPIG). (21). Another interesting fact in our follow up data is the absence of spontaneous remissions of PNH typical GPI-AP deficient populations which had been reported. A study with 35 pts referred a rate of 15 % spontaneous remissions (6) in PNH pts but available GPI-AP flow cytometric results and even HAM-test were limited in this study. All observed remissions in our patient group happened in the context of stem cell transplantation or intensified immunosuppressive therapy especially in patients with AA-PNH-syndrome. The reported 3 patients with classical PNH and decrease of the GPI-AP deficient population on granulocytes below 50% developed an increase over 50 % GPI-deficient cells on the granulocytes during further follow up.

Generally, expression of GPI-anchored proteins should be analysed in all situations suspicious of PNH and in bone marrow failure syndromes. According to our data measurement of at least two different GPI-anchored proteins on granulocytes, erythrocytes and reticulocytes provides a simple and rapid method to detect even small GPI-deficient populations. Measurement of erythrocytes only includes the pitfall of false negative results or false low values of GPI-deficient populations. On the contrary examination of GPI-deficiency on reticulocytes additionally prevents false positive interpretation of significant GPI-deficient populations on the leukocytes (data supplements). GPI-AP-deficiencies without clinical PNH were reported in the context of other hematologic diseases or after immunosuppressive therapy (26) as well as in healthy individuals (27, 28). Our data demonstrate that in patients with small GPI-deficient populations these can in particular be detected on monocytes. In conclusion we recommend a flow cytometric screening panel with the markers CD58 and CD59 on reticulocytes and erythrocytes as well as with the markers CD24/66b and CD16 on granulocytes for initial diagnosis and monitoring during follow up. In case of significant GPI-AP-deficient population in a minimum of one cell lineage the analysis should be extended to the markers CD14 and CD48 on monocytes. Furthermore we advise a serial monitoring for PNH-pts as well as for pts with bone marrow failure syndromes without a present GPI-AP-deficiency every 6 months or in case of significant clinical symptoms.
Recently Richards et al (29) showed that a relevant proportion of laboratories doing PNH-testing by flow cytometry have significant problems with regard to false-positive and false-negative results. On the other hand due to the advent of a new targeted therapy option early diagnosis and serial monitoring of PNH is gaining importance for a better patient management (30). As a consequence, there is the urgent need for optimized flow cytometric protocols in PNH diagnosis. In conclusion, this analysis has demonstrated that the described flow cytometric method offers significant benefits in sensitivity and validity in PNH testing and can be therefore recommended for a wider use.

Authorship and Disclosures
BH and HS took primary responsibility for the paper and designed research. BH and MR performed laboratory work. BH, HS and MR analysed the data and wrote the paper.
BH and HS were advisors for and received honoria from Alexion. MR reported no potential conflicts of interest.

Running head:
B. Höchsmann and H. Schrezenmeier et al.
Flow cytometric analysis for PNH
References

1. Dacie JV: Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963; 56: 587-596

2. Oni SB, Osunkoya BO, Luzzatto L: Paroxysmal nocturnal hemoglobinuria: Evidence of monoclonal origin of abnormal red cells. Blood 1970; 36: 145-152

3. Myata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, Maeda K, Kitani T, Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259: 1318-1320

4. Mortazavi Y, Merk B, McIntosh J, Marsh JC, Schrezenmeier H, Rutherford TR; BIOMED II Pathophysiology and Treatment of Aplastic Anaemia Study Group. The spectrum of PIG-A mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria: a high incidence of multiple mutations and evidence of a mutational hot spot. Blood. 2003 Apr 1;101(7):2833-41.

5. Bessler M, Mason PJ, Hillmen P, Miyata T, Yamada N, Takeda N, Luzzatto L, Kinoshita T: Paroxysmal nocturnal hemoglobinuria is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13: 110-117

6. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Eng J 1995; 333: 1253-1258

7. Nebe T, Schubert J, Schrezenmeier H: Flow Cytometric Analysis of GPI-deficient Cells for the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria and PNH-Syndrome; 2002.,

8. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de GS, Maury S, Cahn JY, Socie G: Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008;112:3099-3106.

9. Hernandez-Campo PM, Almeida J, Acevedo MJ, Sanchez ML, Alberca I, Vidrailes B, Martinez E, Romero JR, Orfao A: Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. Transfusion 2008;48:1403-1414.

10. Richards SJ, Hillmen P: Immunophenotypic analysis of PNH cells. Curr Protoc Cytom 2002;Chapter 6:Unit.

11. Nebe T, Schubert, J., Gutenson, K., Schrezenmeier H: Flow cytometric analysis of GPI-deficient cells for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). J Lab Med 2003;27:257-265.

12. Schrezenmeier H, Hildebrand A, Rojewski M, Hacker H, Heimpel H, Raghavachar A: Paroxysmal nocturnal haemoglobinuria: a replacement of haematopoietic tissue? Acta Haematol 2000;103:41-48.

13. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA: Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004;126:133-138.

14. Richards SJ; Barnett D The role of flow cytometry in the diagnosis of PNH in the clinical laboratory, Clin Lab Med 2007; 27; 577-590
15. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in PNH. Blood. 2003; 102:3587-3591

16. Hillmen P, Muus P, Dührsen U, Risitano A, Schubert J, Luzzatto L, Schrezenmeier H, Jeffrey S, Brodsky RA, Hill A, Socie G, Bessler M, Rollins S, Bell L, Rother R, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110, 12: 4123-4128

17. Schrezenmeier H & Höchsmann B. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Reviews Hematol. 2 (1), 7-16 (2009)

18. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of PNH. Br J Haematol. 2007; 137:181-192

19. Hill A, Hillmen P, Richards SJ et al. Sustained response and long term safety of eculizumab in PNH. Blood 2005, 106:2559-2265

20. Schrezenmeier H, Hertenstein B, Wagner B et al.: A pathogenetic link between aplastic anemia and paroxysmal nocturnal haemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phophatidylinositol glycan anchored proteins. Exp. Hematol 1995;23:81-87;

21. Parker C, Omine M, Socie G. et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106, 12: 3699-3709

22. Hall Se, Rosse WF: The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87: 5332-5340

23. Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal emoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114: 459-466

24. Rosse WF, Dacie JV: Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. J Clin Invest 1966, 45(5): 736-745

25. Navenot JM, Muller JY, Blanchard D: Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion 1998 38 (4): 337-42

26. Taylor VC, Sims M, Brett S, Field MC: Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in lymphocytes by a novel mechanism. Biochem J, 1997; 322: 919-25

27. Young NS: The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood; 1992 79 (6): 1385-92

28. Bessler M, Mason P, Hillmen P, Luzzatto L: Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet; 1994; 343 (8903): 951-3

29. Richards SJ, Whitby L., Cullen MJ, Barnett D et al.: Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. Cytometry Part B (Clinical Cytometry); 2009; 76 B:47-55

30. Schrezenmeier H & Höchsmann B: Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Reviews of Hematology; 2009; 2 (1): 7-16
31. Wang SA, Pozdnyakova O, Jorgensen JL, Medelros J, Stachurski D, Anderson M, Raza A, Woda BA: Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica; 2009; 94(1): 29-37

32. Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF, Fischer AM, Socié G; French Society of Hematology: Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica. 2010 Apr;95(4):574-81.

33. Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, Richards SJ, Bessler M, Bell L, Hillmen P, Gladwin MT.: Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010 May;149(3):414-25.
Figure Legends:

Figure 1: Staining of the reticulocytes by the RNA dye thiazol orange allowed a separate analysis of erythrocytes and reticulocytes. Comparison of the results in a healthy control and a PNH-patient. In the healthy control separation of two populations according to erythrocytes (left upper quadrant) and reticulocytes (right upper quadrant) without significant GPI-deficiency. In the PNH patient separation of four populations according to erythrocytes and reticulocytes without (upper quadrants) and with (lower) significant GPI-deficiency.

Figure 2: Flow sheet patient of the different patient groups at time of initial GPI-AP-analysis and during follow up. Significant changes of GPI-deficient populations during follow up was observed in groups B, D1, D2 with an expansion of GPI-AP deficient populations (including new PNH-diagnosis) and in groups E1, E2 and F with an decrease of GPI-AP deficient populations (including disapperance of PNH diagnosis criteria).

Figure 3: Correlation between the used GPI-AP markers within one cell line. Black = all analyses. Red = restricted to the first analysis per patient. Broken black lines = confidence interval of all analyses. Broken red lines = confidence interval of the first analysis per patient. All correlations were highly significant (p < 0.0001) in the group with all analyses as well as in the group with only the first analysis (p < 0.0001). The range of the correlation coefficient was r² = 0.61 - 0.95.

Figure 4: Correlation between the used GPI-AP markers on the different cell lines. Black = all analyses. Red = restricted to the first analysis per patient. Broken black lines = confidence interval of all analyses. Broken red lines = confidence interval of the first analysis per patient. All correlations were highly significant in the group with all analyses (p < 0.0001) as well as in the group with only the first analysis (p < 0.0001). The range of the correlation coefficient was r² = 0.33 up to 0.88. The lowest value for r² (r² = 0.33) was observed between CD59 on erythrocytes and CD24/CD66b on granulocytes, whereas the correlation between CD59 on reticulocytes and CD24/CD66b on granulocytes was r² = 0.60.

Figure 5: Scatter blots with marker deficient cells in % in pts with > 10% GPI-deficient granulocyte population (B + D) and in pts with < 10% GPI-deficient granulocyte population (A + C). ECD58 = CD58-deficiency on erythrocytes, ECD59 = CD59-deficiency on erythrocytes, RCD58 = CD58-deficiency on reticulocytes, RCD59 = on reticulocytes, GCD24/66b = CD24/66b-deficiency on granulocytes, GFLAER or GCD16 = CD16 and/or FLAER or CD16-deficiency on granulocytes, MCD14 = CD14-deficiency on monocytes, MCD48 = CD48 deficiency on monocytes. Blue line median size of GPI-deficient population.

Figure 6: examples of follow up courses for each follow up subgroup A-F. (A) flow cytometric criteria for PNH at initial diagnosis and during follow up not fullfilled; (B) new flow cytometric diagnosis of PNH during follow up; (C) stable GPI-deficiency during follow up; (D) increase of GPI-deficiency during follow up; (E) decrease of GPI-deficiency during follow up; (F) flow cytometric diagnosis criteria for PNH lost during follow up.
Figure 7: Scatter plots of GPI-marker deficiency in % during follow up. ECD59 = CD59-deficiency on erythrocytes, RCD59 = on reticulocytes, GCD24/66b = CD24/66b-deficiency on granulocytes, MCD14 = CD14-deficiency on monocytes. Blue line: median size of GPI-deficient population. First examination = results of group B (no flow cytometric PNH-diagnosis at first GPI-AP-analysis, but fulfilling flow cytometric PNH diagnosis criteria during follow up) at time of initial GPI-AP-analysis. Initial diagnosis = results of group C + D + E + F (flow cytometric PNH diagnosis at first GPI-AP analysis) at time of first GPI-AP-analysis and results of group B at time of first flow cytometric PNH diagnosis. Last follow up: results of all patients with flow cytometric PNH diagnosis at time of last GPI-AP analysis.
Figure 1: Staining of the reticulocytes by the RNA dye thiazol orange allowed a separate analysis of erythrocytes and reticulocytes. Comparison of the results in a healthy control and a PNH patient. In the healthy control separation of two populations according to erythrocytes (left upper quadrant) and reticulocytes (right upper quadrant) without significant GPI-deficiency. In the PNH patient separation of four populations according to erythrocytes and reticulocytes without (upper quadrants) and with (lower) significant GPI-deficiency.
Figure 2: Flow sheet patient of the different patient groups at time of initial GPI-AP-analysis and during follow up. Significant changes of GPI-deficient populations during follow up was observed in groups B, D1, D2 with an expansion of GPI-AP deficient populations (including new PNH-diagnosis) and in groups E1, E2 and F with a decrease of GPI-AP deficient populations (including disappearance of PNH diagnosis criteria).
Figure 3: Correlation between the used GPI-AP markers within one cell line. Black = all analyses. Red = restricted to the first analysis per patient. Broken black lines = confidence interval of all analyses. Broken red lines = confidence interval of the first analysis per patient. All correlations were highly significant (p < 0.0001) in the group with all analyses as well as in the group with only the first analysis (p < 0.0001). The range of the correlation coefficient was r² = 0.61 - 0.95.
Figure 4: Correlation between the used GPI-AP markers on the different cell lines. Black = all analyses. Red = restricted to the first analysis per patient. Broken black lines = confidence interval of all analyses. Broken red lines = confidence interval of the first analysis per patient. All correlations were highly significant in the group with all analyses (p < 0.0001) as well as in the group with only the first analysis (p < 0.0001). The range of the correlation coefficient was $r^2 = 0.33$ up to 0.88. The lowest value for $r^2$ ($r^2 = 0.33$) was observed between CD59 on erythrocytes and CD24/CD66b on granulocytes, whereas the correlation between CD59 on reticulocytes and CD24/CD66b on granulocytes was $r^2 = 0.60$. 
Figure 5: Scatter blots with marker deficient cells in % in pts with $\geq$ 10% GPI-deficient granulocyte population (B + D) and in pts with $< 10$% GPI-deficient granulocyte population (A + C). ECD58 = CD58-deficiency on erythrocytes, ECD59 = CD59-deficiency on erythrocytes, RCD58 = CD58-deficiency on reticulocytes, RCD59 = CD59-deficiency on reticulocytes, GCD24/66b = CD24/66b-deficiency on granulocytes, GFLAER or GCD16 = CD16 and/or FLAER or CD16-deficiency on granulocytes, MCD14 = CD14-deficiency on monocytes, MCD48 = CD48 deficiency on monocytes. Blue line median size of GPI-deficient population.
Figure 6: examples of follow up courses for each follow up subgroup A-F. (A) flow cytometric criteria for PNH at initial diagnosis and during follow up not fulfilled; (B) new flow cytometric diagnosis of PNH during follow up; (C) stable GPI-deficiency during follow up; (D) increase of GPI-deficiency during follow up; (E) decrease of GPI-deficiency during follow up; (F) flow cytometric diagnosis criteria for PNH lost during follow up.
Figure 7: Scatter blots of GPI-marker deficiency in % during follow up. ECD59 = CD59-deficiency on erythrocytes, RCD59 = on reticulocytes, GCD24/66b = CD24/66b-deficiency on granulocytes, MCD14 = CD14-deficiency on monocytes. Blue line median size of GPI-deficient population. First examination = results of group B (no flow cytometric PNH-diagnosis at first GPI-AP-analysis, but fulfilling flow cytometric PNH diagnosis criteria during follow up) at time of initial GPI-AP-analysis. Initial diagnosis = results of group C + D + E + F (flow cytometric PNH diagnosis at first GPI-AP analysis) at time of first GPI-AP-analysis and results of group B at time of first flow cytometric PNH diagnosis. Last follow up: results of all patients with flow cytometric PNH diagnosis at time of last GPI-AP analysis.
Tables:

Table 1: Patient characteristics of all pts at initial analysis and separated in the groups with and without flow cytometric PNH diagnosis at initial GPI-AP analysis as well as of the patient groups A - F regarding to number, sex distribution, age, follow up duration, GPI-AP-examination number and GPI-AP examination number up to a significant change during follow up.

| group definition | Patients N (%) | Female | Male | age; median (years) | age; min.-max. (years) | follow up; median (days) | follow up; (min. – max.) (days) | GPI-AP-examinations; median (min. – max.) | GPI-AP-examinations up to relevant change* | median (min. – max.) |
|------------------|----------------|--------|------|---------------------|------------------------|-------------------------|---------------------------------|------------------------------------------|----------------------------------------|---------------------|
| all patients     | 803 (100%)     | 382    | 416  | 32.4                | 0.4 – 90.7             |                         |                                 |                                           |                                        |                     |
| patients without flow cytometric PNH diagnosis at initial analysis | 627 (78%) | 302    | 320  | 34.3                | 0.4 – 90.7             |                         |                                 |                                           |                                        |                     |
| patients with flow cytometric PNH diagnosis at initial analysis | 176 (22%) | 80     | 96   | 31.0                | 3.9 – 81.4             |                         |                                 |                                           |                                        |                     |
| patients with follow up | 155 | 75     | 80   |                  | 1.3 - 82.5             | 1039                    | 90 - 1903                      | 3 (2 -26)                  | (2 -26)                  |                     |
| A no flow cytometric PNH – diagnosis at initial examination and during follow up | 73 (47%) | 34     | 39   | 15.6                | 1.3 - 82.5             | 365                     | 98 - 1632                      | 2 (2 – 11)                  |                                  |                     |
| B new flow cytometric PNH – diagnosis during follow up | 7 (4.5%) | 2      | 5    | 20.6                | 16.6 - 64.4            | 1585                    | 112 - 1903                     | 5 (2 – 11)                  |                                  |                     |
| C GPI-AP-deficient population | 54 (35%) | 31     | 23   | 32.2                | 12.7 - 80.1            | 489                     | 90 - 1786                      | 3 (2 – 18)                  |                                  |                     |
| Relevant change during follow up was defined as *(B) new flow cytometric diagnosis of PNH during follow up after a normal GPI-AP-expression at first investigation; *(D) increase of GPI-deficient granulocyte population from < 50% to ≥ 50%) and/or involvement of additional cell lineages during follow up; *(E) decrease of GPI-deficient granulocyte population from ≥ 50% to < 50%) or disappearance of GPI-deficiency in a cell lineage during longitudinal analysis; *(F) disappearance of the PNH-typical GPI-AP deficiency below our criteria for flow cytometric PNH diagnosis. |
Follow up analysis
Patients $n = 155$

Blood count at initial examination $n = 89$
- Significant GPI-AP deficient clone and blood count at initial examination $n = 36$
  - Neutrophiles $< 0.5 \text{ G/l}$ $n = 8$
  - Thrombocytes $< 100 \text{ G/l}$ $n = 20$
- No GPI-AP deficient clone and blood count at initial examination $n = 53$
  - Neutrophiles $< 0.5 \text{ G/l}$ $n = 24$
  - Thrombocytes $< 100 \text{ G/l}$ $n = 35$

Blood count at last examination $n = 120$
- Significant GPI-AP deficient clone and blood count at last examination $n = 56$
  - Neutrophiles $< 0.5 \text{ G/l}$ $n = 7$
  - Thrombocytes $< 100 \text{ G/l}$ $n = 22$
- No GPI-AP deficient clone and blood count at last examination $n = 64$
  - Neutrophiles $< 0.5 \text{ G/l}$ $n = 14$
  - Thrombocytes $< 100 \text{ G/l}$ $n = 29$

Data supplements 1: Flow sheet additional cytopenias in follow up pts
Data supplements 2: a case report of false positive interpretation of significant GPI-deficient populations on leucocytes: patient was diagnosed in an external laboratory to have a significant PNH and eculizumab therapy was started. After the patient developed an ischemic stroke a blood sample was taken and sent to us for confirmation of the diagnosis. Due to the large GPI-deficient populations on the monocytes in combination with the almost normal reticulocytes we suspected immature myeloid cells. Consecutively a bone marrow assessment confirmed an AML M7 with a blast excess and a chemotherapy was started.